TCRX TScan Therapeutics Forecast, Technical & Fundamental Analysis
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer... Show more
TCRX is expected to report earnings to rise 17.91% to -25 cents per share on August 19
Q2'26
Est.
$-0.26
Q1'26
Missed
by $0.04
Q4'25
Beat
by $0.09
Q3'25
Beat
by $0.06
Q2'25
Beat
by $0.05
The last earnings report on May 07 showed earnings per share of -21 cents, missing the estimate of -18 cents. With 648.89K shares outstanding, the current market capitalization sits at 67.31M.
A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with MGX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then MGX could also see price increases.
TCRX's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for TCRX moved out of overbought territory on July 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where TCRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TCRX broke above its upper Bollinger Band on July 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TCRX entered a downward trend on July 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 26, 2026. You may want to consider a long position or call options on TCRX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TCRX just turned positive on June 26, 2026. Looking at past instances where TCRX's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
TCRX moved above its 50-day moving average on July 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TCRX crossed bullishly above the 50-day moving average on July 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TCRX advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.694) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). TCRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (14.641) is also within normal values, averaging (434.181).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
